Patheon, an Amsterdam-based contract drug developer, said in a regulatory filing it plans to raise $625 million in a public offering that analysts forecast would give the company a market value of ...

Patheon is awaiting finalization of a $7.2 billion deal that will make it a part of Thermo Fisher Scientific, but in the meantime the CDMO is moving forward with expansion plans at sites that stretch ...

DURHAM, NC--(Marketwired - September 28, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today ...

May 15 (Reuters) - Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, said on Monday it would buy contract manufacturing company Patheon NV for about $5.2 billion in ...

TORONTO, Nov. 19, 2013 /CNW/ – Patheon Inc. (TSX:PTI) (“Patheon”) today announced that it has entered into an arrangement agreement (the “Arrangement Agreement”) with JLL/Delta Patheon Holdings, L.P., ...

In response to the company accepting a buyout offer, shares of Patheon N.V. (NYSE: PTHN) , a provider of development and manufacturing services for the pharmaceutical industry, jumped 33% as of 10:45 ...

(Reuters) - Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in ...

Says believes Lonza bid in the best interests of co Says JLL cannot unilaterally dictate future of Patheon Welcomes expiry of JLL's $2-a-share bid TORONTO, Aug 28 (Reuters) - Canadian drug ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Thermo Fisher Scientific on Monday unveiled a $7.2bn deal to buy Patheon, a company that helps biotech and ...